Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trialSarah Brown, Jonathan Wadsley, Laura Moss et al.|BMC Cancer|2019Cited by 39
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah Buckley, Naveen Vasudev, Fiona Collinson et al.|BMC Cancer|2019Cited by 17
PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaFiona Collinson, Naveen Vasudev, Sarah Brown et al.|Annals of Oncology|2018Cited by 2